Ravi Dhawale, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1023051299
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,300 of the $175,232 with a category attached, or 88.6%. AstraZeneca accounts for 66.4% of it on its own, with 58 other manufacturers making up the rest. Reporting peaked in 2019 at $93,198 and has fallen 97.5% since, to $2,355 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 854 payments — averaging $205.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$116K
- Amgen$47K
- Dexcom, Inc.$2K
- Xeris Pharmaceuticals, Inc.$1K
- Novo Nordisk$1K
- Insulet Corporation$765
- plus $7K from 53 others
What the payments were for
- Speaking & faculty fees$155,30089%
- Travel & lodging$4,1932%
- Food & beverage$15,7019%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$114,088
- EVENITY$22,616
- Prolia$22,307
- DEXCOM G6 TRANSMITTER$220
- GVOKE HYPOPEN$135
- GVOKE PFS$123
- Ozempic$121
How this compares
$175,232 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $262,205 |
| Teriparatide | 88 | $240,035 |
| OzempicSemaglutide | 99 | $172,989 |
| ForteoTeriparatide | 29 | $120,707 |
| MounjaroTirzepatide | 79 | $113,603 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $96,948 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 66 | $96,163 |
| JardianceEmpagliflozin | 60 | $75,954 |
| FarxigaDapagliflozin Propanediol | 57 | $71,423 |
| TrulicityDulaglutide | 36 | $66,987 |
| ProliaDenosumab | 23 | $39,689 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $34,796 |
| Repatha SureclickEvolocumab | 25 | $33,219 |
| TymlosAbaloparatide | 12 | $31,228 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $24,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro, Trulicity, Humalog | $584 | $314,856174 claims |
| Corcept TherapeuticsKorlym | $329 | $262,20513 claims |
| Novo NordiskOzempic, Novolog | $1,086 | $182,569120 claims |
| Boehringer IngelheimJardiance | $326 | $75,95460 claims |
| AstraZenecaFarxiga | $116,327 | $71,42357 claims |
| AmgenProlia | $46,938 | $39,68923 claims |
| Radius Health, Inc.Tymlos | $92 | $31,22812 claims |
| MerckJanuvia | $69 | $22,18117 claims |
| AbbVieSynthroid, Armour Thyroid | $163 | $19,610261 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $213 | $7,479586 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Laura RyanColumbus$126K
- Kathleen WyneColumbus$88K
- Kathleen DunganColumbus$60K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
- Laura ButzColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.